Lotus Pharmaceuticals, Inc.
LTUS · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $14 | $19 | $21 | $30 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14 | $19 | $21 | $30 |
| Operating Income | -$14 | -$19 | -$21 | -$30 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $125 | $0 | $0 | -$0 |
| Pre-Tax Income | $111 | -$19 | -$21 | -$30 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $111 | -$19 | -$21 | -$30 |
| % Margin | – | – | – | – |
| EPS | 0 | 0 | 0 | 0 |
| % Growth | – | – | – | – |
| EPS Diluted | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out | 2,691,647 | 2,694,516 | 2,694,516 | 2,944,516 |
| Weighted Avg Shares Out Dil | 2,691,647 | 2,694,516 | 2,694,516 | 2,944,516 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $168 | $228 | $237 |
| EBITDA | $111 | -$19 | -$21 | -$30 |
| % Margin | – | – | – | – |